CoChat

Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays

Open access
Daniels, V, Wood, M, Leclercq, K, Kaminski, R M, Gillard, M · 2013 · British Journal of Pharmacology
Cited by 28

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Background and Purpose: Synaptic vesicle protein 2A(SV2A) is the specific binding site of the anti‐epileptic drug levetiracetam (LEV) and its higher affinity analogue UCB30889. Moreover, the protein has been well validated as a target for anticonvulsant therapy. Here, we report the identification of UCB1244283 acting as a SV2A positive allosteric modulator of UCB30889. Experimental Approach: UCB1244283 was characterized in vitro using radioligand binding assays with[3 H]UCB30889 on recombinant SV2A expressed in HEK cells and on rat cortex.In vivo, the compound was tested in sound‐sensitive mice. Key Results: Saturation binding experiments in the presence of UCB1244283 demonstrated a fivefold increase in the affinity of[3 H]UCB30889 for human recombinant SV2A, combined with a twofold increase of the total number of binding sites. Similar results were obtained on rat cortex. In competition binding experiments,UCB1244283 potentiated the affinity of UCB30889 while the affinity of LEV remained unchanged.UCB1244283 significantly slowed down both the association and dissociation kinetics of[3 H]UCB30889. Following i.c.v. administration in sound‐sensitive mice,UCB1244283 showed a clear protective effect against both tonic and clonic convulsions. Conclusions and Implications: These results indicate that UCB1244283 can modulate the conformation of SV2A, thereby inducing a higher affinity state for UCB30889. Our results also suggest that the conformation of SV2A per se might be an important determinant of its functioning, especially during epileptic seizures. Therefore, agents that act on the conformation of SV2A might hold great potential in the search for new SV2A‐based anticonvulsant therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.12192

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 28

Metadata

Authors
Daniels, V, Wood, M., Leclercq, K., Kaminski, R. M., & Gillard, M.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2013-06-12
Volume
169
Issue
5
Pages
1091-1101
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1505043869
Cited by
28
References
10
FWCI
0.87
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.